Science-driven commentary on drug discovery, therapeutic innovation, and the evolving landscape of the biopharmaceutical industry.
The meteoric rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed the treatment landscape for obesity and type 2 diabetes. But as these drugs reshape the market, fundamental questions remain: Are we treating the right target? What are the long-term implications? And who truly benefits?
In this article, Dr. Jedinak offers a balanced scientific perspective on the pharmacological mechanisms, clinical utility, and broader strategic implications of the GLP-1 agonist revolution — and what it means for drug discovery in metabolic disease.
Topics in immuno-oncology, checkpoint biology, and tumor microenvironment research. Subscribe below to be notified.
Articles on pharmacology strategy, target validation approaches, and translational science best practices.
Perspectives on rare disease drug development, orphan designations, and patient-centric development strategies.
Subscribe to receive new articles and insights directly in your inbox — no spam, unsubscribe anytime.
No spam. Scientific insights only. Unsubscribe anytime.